|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"akimov m"
Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; Chia-Chi Lin; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. |
| 臺大學術典藏 |
2020-12-02T02:34:19Z |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan E.-H.;Ramlau R.;Pluzanska A.;Kuo H.-P.;Reck M.;Milanowski J.;Au J.S.-K.;Felip E.;Pan-Chyr Yang;Damyanov D.;Orlov S.;Akimov M.;Delmar P.;Essioux L.;Hillenbach C.;Klughammer B.;Mcloughlin P.;Baselga J.; Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Chia-Chi Lin; Akimov M; Ghebremariam S; Hong D; Poon R.T.P; Azaro A; Lim W.T; Bauer T.M; Nam D.-H; Schuler M; Su W.-C; Bang Y.-J; Zhao S; Giovannini M; Ma B. |
| 國立成功大學 |
2020 |
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
|
Bang, Y.-J.;Su, W.-C.;Schuler, M.;Nam, D.-H.;Lim, W.T.;Bauer, T.M.;Azaro, Azaro A.;Poon, R.T.P.;Hong, D.;Lin, C.-C.;Akimov, M.;Ghebremariam, S.;Zhao, S.;Giovannini, M.;Ma, B. |
| 國立成功大學 |
2018 |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Wu, Y.-L.;Zhang, L.;Kim, D.-W.;Liu, X.;Lee, D.H.;Yang, J.C.-H.;Ahn, M.-J.;Vansteenkiste, J.F.;Su, W.-C.;Felip, E.;Chia, V.;Glaser, S.;Pultar, Pultar P.;Zhao, S.;Peng, B.;Akimov, M.;Tan, D.S.W. |
Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
